Literature DB >> 7998691

Evaluation of topically administered tissue plasminogen activator for intraocular fibrinolysis in dogs.

P A Gerding1, R E Hamor, D T Ramsey, S Vasaune, D J Schaeffer.   

Abstract

Fibrin clots were induced in eyes of dogs by injection of autogenous citrated plasma into the anterior chamber. Twenty-four hours after clot formation, one 50-microliters drop of tissue plasminogen activator at a concentration of 5 mg/ml (group 1, n = 7) was administered topically 9 times at 5-minute intervals, or a collagen shield that was hydrated with tissue plasminogen activator at a concentration of 5 mg/ml (group 2, n = 7) was applied. The contralateral eye served as a nontreated control. Serial photographs were taken of the fibrin clots after topical application of tissue plasminogen activator. Computerized morphometric analysis was then used to evaluate changes in cross-sectional surface area of the fibrin clot. There was no significant mean percentage decrease in clot surface area of treated eyes of group-1 dogs or in treated eyes of group-2 dogs. In addition, there was no significant difference in mean percentage decrease in clot surface area between treated eyes of group-1 and group-2 dogs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998691

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  2 in total

1.  Recombinant tissue plasminogen activator following paediatric cataract surgery.

Authors:  J S Mehta; G G Adams
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

2.  Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.

Authors:  H Siatiri; A H Beheshtnezhad; H Asghari; N Siatiri; S Moghimi; N Piri
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.